Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 8—August 2012
Peer Reviewed Report Available Online Only

Infectious Disease Transmission during Organ and Tissue Transplantation

Melissa A. GreenwaldComments to Author , Matthew J. Kuehnert, and Jay A. Fishman
Author affiliations: Food and Drug Administration, Rockville, Maryland, USA (M.A. Greenwald); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.J. Kuehnert); Massachusetts General Hospital, Boston, Massachusetts, USA (J.A. Fishman); and Harvard Medical School, Boston (J.A. Fishman)

Main Article

Table 2

Organizations involved in detection, investigation, and communication of organ and tissue transplant–associated infections

Organization and website Role
Food and Drug Administration Regulates transplantation of human cells and tissues and requires Food and Drug Administration–regulated tissue establishments to investigate and report serious adverse events related to infectious disease transmission
Organ Procurement and Transplant Network Operated by the United Network for Organ Sharing under contract with the Health Resources and Services Administration

Reporting Line

Reporting mechanism for potential patient safety issues and Organ Procurement and Transplant Network policy violations

Disease Transmission Advisory Committee

Organ Procurement and Transplant Network committee that compiles all potential transplantation-transmitted infection cases reported to the United Network for Organ Sharing
Council of State and Territorial Epidemiologists Public health reporting and investigation of suspected transplant–transmitted notifiable diseases and illness clusters are coordinated by public health epidemiologists, as described in a 2010 position statement
Centers for Disease Control and Prevention Provides assistance to health departments on organ and tissue transplant–associated adverse events
The Joint Commission Accredits and certifies >18,000 health care organizations and programs in the United States; mandates reporting of tissue adverse patient reactions to the donor source facility

Main Article

Page created: July 11, 2012
Page updated: July 11, 2012
Page reviewed: July 11, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.